×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ENTA – enanta pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ENTA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/19
03:03 pm
enta
Enanta: Maintaining Buy Rating Based On Zelicapavir Potential In RSV Development [Seeking Alpha]
Low
Report
Enanta: Maintaining Buy Rating Based On Zelicapavir Potential In RSV Development [Seeking Alpha]
11/17
04:45 pm
enta
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025 [Yahoo! Finance]
Low
Report
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025 [Yahoo! Finance]
11/17
04:12 pm
enta
Enanta Pharma GAAP EPS of -$0.87, revenue of $15.1M [Seeking Alpha]
Medium
Report
Enanta Pharma GAAP EPS of -$0.87, revenue of $15.1M [Seeking Alpha]
11/17
04:01 pm
enta
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025
Low
Report
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025
11/14
08:09 am
enta
Enanta Pharmaceuticals (NASDAQ:ENTA) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $17.00 price target on the stock.
Low
Report
Enanta Pharmaceuticals (NASDAQ:ENTA) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $17.00 price target on the stock.
11/4
07:00 am
enta
Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences
Low
Report
Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences
10/24
12:22 pm
enta
Enanta Pharmaceuticals (NASDAQ:ENTA) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Enanta Pharmaceuticals (NASDAQ:ENTA) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
10/20
07:00 am
enta
Enanta Pharmaceuticals Presents New Data for Zelicapavir, its N-Protein Inhibitor, and EDP-323, its L-Protein Inhibitor, Both in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025
Low
Report
Enanta Pharmaceuticals Presents New Data for Zelicapavir, its N-Protein Inhibitor, and EDP-323, its L-Protein Inhibitor, Both in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025
Date
Time
Symbol
Company Name
Action
%Chg
8/11/2025
04:02 pm
ENTA
enanta pharmaceuticals, inc.
BEAT
Report
1.5%
enanta pharmaceuticals, inc.
2/10/2025
04:01 pm
ENTA
enanta pharmaceuticals, inc.
BEAT
Report
14.1%
enanta pharmaceuticals, inc.
2/10/2025
04:01 pm
ENTA
enanta pharmaceuticals, inc.
BEAT
Report
14.1%
enanta pharmaceuticals, inc.
2/10/2025
04:01 pm
ENTA
enanta pharmaceuticals, inc.
BEAT
Report
14.1%
enanta pharmaceuticals, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/3
05:09 pm
enta
Form 4 ENANTA PHARMACEUTICALS For: Dec 01 Filed by: Capps Kathleen S.
Low
Report
Form 4 ENANTA PHARMACEUTICALS For: Dec 01 Filed by: Capps Kathleen S.
12/3
05:05 pm
enta
Form 4 ENANTA PHARMACEUTICALS For: Dec 01 Filed by: Trout Harry R. III
Low
Report
Form 4 ENANTA PHARMACEUTICALS For: Dec 01 Filed by: Trout Harry R. III
12/3
05:02 pm
enta
Form 4 ENANTA PHARMACEUTICALS For: Dec 01 Filed by: Luu Brendan
Low
Report
Form 4 ENANTA PHARMACEUTICALS For: Dec 01 Filed by: Luu Brendan
12/3
04:38 pm
enta
Form 4 ENANTA PHARMACEUTICALS For: Dec 01 Filed by: Kieffer Tara Lynn
Low
Report
Form 4 ENANTA PHARMACEUTICALS For: Dec 01 Filed by: Kieffer Tara Lynn
12/3
04:36 pm
enta
Form 4 ENANTA PHARMACEUTICALS For: Dec 01 Filed by: Or Yat Sun
Low
Report
Form 4 ENANTA PHARMACEUTICALS For: Dec 01 Filed by: Or Yat Sun
12/3
04:34 pm
enta
Form 4 ENANTA PHARMACEUTICALS For: Dec 01 Filed by: Luly Jay R.
Low
Report
Form 4 ENANTA PHARMACEUTICALS For: Dec 01 Filed by: Luly Jay R.
11/26
05:25 pm
enta
Form 4 ENANTA PHARMACEUTICALS For: Nov 25 Filed by: Capps Kathleen S.
Low
Report
Form 4 ENANTA PHARMACEUTICALS For: Nov 25 Filed by: Capps Kathleen S.
11/26
05:21 pm
enta
Form 4 ENANTA PHARMACEUTICALS For: Nov 25 Filed by: Trout Harry R. III
Low
Report
Form 4 ENANTA PHARMACEUTICALS For: Nov 25 Filed by: Trout Harry R. III
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/17
Baird likes Enanta's potential in COVID-19, upgrades to Outperform [Seeking Alpha]
11.2%
3/13 Enanta Pharmaceuticals Announces Efforts to Discover a Treatment for the Novel Coronavirus Disease COVID-19 9.2%
2/28 Form 4 ENANTA PHARMACEUTICALS For: Feb 26 Filed by: Russell Lesley 4.1%
5/7 Q2/2019 3/31/2019 EPS 0.200 ZacksConsensus -0.090 ActVsEst 0.290 - Beat 3.8%
2/18 Form 4 ENANTA PHARMACEUTICALS For: Feb 12 Filed by: Luly Jay R. 3.4%
2/3 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 3.3%
8/12 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 3.3%
11/22 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 3.2%
9/10 New Data from Enanta’s Phase 2a Human Challenge Study of EDP-938 for RSV to be Presented at IDWeek™ 2019 3.2%
6/26 Enanta And AbbVie On EDP-305: Assessing Any Future Collaboration In Liver Diseases [Seeking Alpha] 3.1%
3/13 Enanta Pharmaceuticals Announces Efforts to Discover a Treatment for the Novel Coronavirus Disease COVID-19 9.2%
2/28 Form 4 ENANTA PHARMACEUTICALS For: Feb 26 Filed by: Russell Lesley 4.1%
5/7 Q2/2019 3/31/2019 EPS 0.200 ZacksConsensus -0.090 ActVsEst 0.290 - Beat 3.8%
2/18 Form 4 ENANTA PHARMACEUTICALS For: Feb 12 Filed by: Luly Jay R. 3.4%
2/3 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 3.3%
8/12 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 3.3%
11/22 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 3.2%
9/10 New Data from Enanta’s Phase 2a Human Challenge Study of EDP-938 for RSV to be Presented at IDWeek™ 2019 3.2%
6/26 Enanta And AbbVie On EDP-305: Assessing Any Future Collaboration In Liver Diseases [Seeking Alpha] 3.1%
TOP News Decliners
3/14
Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating.
-24.0%
6/14 REFILE-Enanta's lung infection therapy succeeds in mid-stage trial [Reuters] -15.3%
9/25 Enanta Announces Positive Results of ARGON-1 Study of its lead FXR Agonist, EDP-305, for the Treatment of NASH -15.1%
4/30 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -5.8%
3/26 Enanta Provides Update on Clinical Development Activities During COVID-19 Pandemic -5.4%
2/10 Form 10-Q ENANTA PHARMACEUTICALS For: Dec 31 -5.2%
11/21 Q4/2019 9/30/2019 EPS 0.440 ZacksConsensus 0.560 ActVsEst (0.120) - Miss -4.4%
5/10 Form 10-Q ENANTA PHARMACEUTICALS For: Mar 31 -4.3%
6/22 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -4.2%
1/24 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. -3.7%
6/14 REFILE-Enanta's lung infection therapy succeeds in mid-stage trial [Reuters] -15.3%
9/25 Enanta Announces Positive Results of ARGON-1 Study of its lead FXR Agonist, EDP-305, for the Treatment of NASH -15.1%
4/30 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -5.8%
3/26 Enanta Provides Update on Clinical Development Activities During COVID-19 Pandemic -5.4%
2/10 Form 10-Q ENANTA PHARMACEUTICALS For: Dec 31 -5.2%
11/21 Q4/2019 9/30/2019 EPS 0.440 ZacksConsensus 0.560 ActVsEst (0.120) - Miss -4.4%
5/10 Form 10-Q ENANTA PHARMACEUTICALS For: Mar 31 -4.3%
6/22 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -4.2%
1/24 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. -3.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: